3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
39
Ovarian Neoplasms
29
Multiple Myeloma
16
Neoplasms
9
Recurrence
8
Lymphoma
8
Fallopian Tube Neoplasms
8
Triple Negative Breast Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
7
Hodgkin Disease
7
Carcinoma, Ovarian Epithelial
7
Lymphoma, Non-Hodgkin
6
Sarcoma
5
Neoplasm Metastasis
5
Burkitt Lymphoma
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Lung Neoplasms
2
Liver Neoplasms
2
Leukemia
2
Leiomyosarcoma
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Disease Progression
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Interventions
Fluorouracil
87
Leucovorin
78
Oxaliplatin
77
Irinotecan
76
Bevacizumab
50
Cetuximab
42
Capecitabine
42
Panitumumab
17
Folfox protocol
16
Floxuridine
11
Chemotherapy, Adjuvant
11
regorafenib
10
IFL protocol
10
Nivolumab
9
Drug Therapy
9
trifluridine tipiracil drug combination
8
Surgical Procedures, Operative
8
Neoadjuvant Therapy
8
sargramostim
7
pembrolizumab
7
XELOX
7
Specimen Handling
7
Biopsy
7
Trastuzumab
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
HMPL-013
6
tislelizumab
5
encorafenib
5
Trifluridine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Colonic Neoplasms
×
liposomal doxorubicin
×
Clear all
NCT01464593
2022-10-13
ABLATE
Imunon
Phase 2
Terminated
2 enrolled
5 charts